Close Menu
Home » Celsee, IncellDx to Commercialize Assays After Cancer Study Collaboration

Celsee, IncellDx to Commercialize Assays After Cancer Study Collaboration

Jan 11, 2018
|
staff reporter

NEW YORK (GenomeWeb) – Celsee said today that it has entered a co-commercialization agreement with IncellDx for several products, including a 20-marker lung cancer genomics and proteomics panel, a CTC-based screening test for breast, colorectal, prostate, and other cancers, and a cell-based NIPT assay.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Letting Samples Fly

Rady Children's Institute for Genomic Medicine and Deloitte are looking into the use of drones to transport samples for testing. 

Layoffs at 23andMe

Direct-to-consumer genetic testing firm 23andMe is laying off about 100 people.

Dusty Resistance

Researchers from Northwestern University examined dust for antibiotic-resistance genes, New Scientist reports. 

Science Studies Use Single-Cell RNA Sequencing to Study Cell States, Apply Deep Phenotyping to Pregnancy

In Science this week: researchers present a computational method for predicting cellular differentiation state from single-cell RNA sequencing data, and more. 

What's Popular?

In Business News

  1. 23andMe Lays off 100 Employees Across Consumer Business

  2. 10x Genomics Lawsuit Over Exclusivity of Harvard Single-Cell IP License Going to Trial

  3. Adaptive Biotechnologies Prices Public Offering of Stock

  4. Federal Court Whittles Down Fluidigm Lawsuit Against IonPath

  5. Quest Diagnostics Acquires Blueprint Genetics

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.